Anzeige
Mehr »
Login
Dienstag, 01.04.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Kurs-Explosion voraus?: Diese kaum bekannte Aktie bohrt jetzt im Hotspot - und du erfährst es als Erster!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
427 Leser
Artikel bewerten:
(1)

Teleglobal Consulting LTD: Teleglobal Consulting receives CE marking for its AI solution

Finanznachrichten News

UK's first CE marked AI software that can detect up to thirteen different chest abnormalities, reading through X-rays

SWINDON, United Kingdom, June 10, 2021 (GLOBE NEWSWIRE) -- Teleglobal Consulting LTD, UK, has received Class 2A CE marking for its AI-based chest abnormality detection software. Teleglobal now joins the league of very few companies in the UK to achieve CE Marking for AI solution in medical imaging. The company makes AI products under the brand "iDoc.ai".

iDoc-X can accurately detect thirteen different abnormalities, including COVID-19. Other disease classes are: pneumothorax, pneumonia, TB, scars, opacities, nodule, cavity, cardiomegaly, consolidation, fibrosis, blunted CP and pleural effusion. The software integrates seamlessly with radiology workflow, detects abnormalities from X-rays and provides "AI Suggestions" in the clinician's worklist. Radiologists can prioritise worklist based on suggested abnormalities.

The software is meant to improve the quality & speed of radiology diagnosis and reduce operational costs associated with radiology outsourcing and second opinion. In addition, the software allows radiology setups to use "one-solution" for most common chest abnormalities.

Since early 2018, iDoc.ai has been progressively working with healthcare partners in India and South East Asia for pilot deployments for iDoc-X. Recent ISO 13485 certification and CE marking allow the company to operate commercially across the EU under the European Union Medical Device Regulation (MDR), and many other countries worldwide.

"CE marking is a very encouraging milestone for us, endorsing our vision of responsible AI and reflecting our passion for quality and patient safety. Our emphasis on regulatory affairs will continue with USFDA and UKCA soon," said Rahul Tarar, MD, iDoc.ai.

The company's executive team believes that, "globally, research on AI-based chest X-ray analysers has progressed well during the last few years. However, as per the University of Toronto, the Vector Institute, and MIT, most AI solutions out in the international market currently are biased towards gender, age, race or socioeconomic status. Research shows that most algorithms are less certain to work well for racial groups from underrepresented countries. The outcomes are often biased towards the specific countries and socioeconomic backgrounds where data for training is gathered from."

Moving forward, the company aims to invest more in the elimination or mitigation of 'bias' completely, enhancing accuracy and creating the world-first bias-free AI solution for medical imaging.

"We very much understand the importance of solution's - reliability & accuracy, and of our marketing efforts for commercial success. Hence, we are actively seeking funding possibilities for further investment into R&D and to achieve quicker time-to-market," Rahul Tarar added.

About Teleglobal Consulting LTD

Teleglobal Consulting LTD is a UK based company focused on harnessing the power of cognitive computing in healthcare through its AI initiative - iDoc.ai (https://idoc.ai/). iDoc.ai's mission is to enable clinicians with the power of AI, enabling them to deliver - accurate, quick and affordable clinical outcomes for patients.

Contact:
Gaurav Kala
+44
press@idoc.ai


© 2021 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.